GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » Piotroski F-Score

Chembio Diagnostics (Chembio Diagnostics) Piotroski F-Score : 5 (As of May. 12, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chembio Diagnostics has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Chembio Diagnostics's Piotroski F-Score or its related term are showing as below:

CEMI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of Chembio Diagnostics was 6. The lowest was 2. And the median was 4.


Chembio Diagnostics Piotroski F-Score Historical Data

The historical data trend for Chembio Diagnostics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics Piotroski F-Score Chart

Chembio Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 2.00 4.00 5.00

Chembio Diagnostics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 4.00 3.00 5.00

Competitive Comparison of Chembio Diagnostics's Piotroski F-Score

For the Diagnostics & Research subindustry, Chembio Diagnostics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chembio Diagnostics's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Net Income was -8.79 + -6.946 + -6.699 + -0.855 = $-23.29 Mil.
Cash Flow from Operations was -4.369 + -0.433 + -5.06 + -2.832 = $-12.69 Mil.
Revenue was 18.817 + 9.161 + 11.2 + 9.162 = $48.34 Mil.
Gross Profit was 3.593 + 1.075 + 1.541 + 3.553 = $9.76 Mil.
Average Total Assets from the begining of this year (Dec21)
to the end of this year (Dec22) was
(73.252 + 62.89 + 56.056 + 62.18 + 62.611) / 5 = $63.3978 Mil.
Total Assets at the begining of this year (Dec21) was $73.25 Mil.
Long-Term Debt & Capital Lease Obligation was $5.51 Mil.
Total Current Assets was $48.45 Mil.
Total Current Liabilities was $39.30 Mil.
Net Income was -4.5 + -9.064 + -6.366 + -13.973 = $-33.90 Mil.

Revenue was 5.374 + 4.182 + 9.658 + 17.712 = $36.93 Mil.
Gross Profit was 1.826 + 0.142 + 1.756 + -1.293 = $2.43 Mil.
Average Total Assets from the begining of last year (Dec20)
to the end of last year (Dec21) was
(64.892 + 57.413 + 49.577 + 84.043 + 73.252) / 5 = $65.8354 Mil.
Total Assets at the begining of last year (Dec20) was $64.89 Mil.
Long-Term Debt & Capital Lease Obligation was $23.71 Mil.
Total Current Assets was $54.85 Mil.
Total Current Liabilities was $15.28 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chembio Diagnostics's current Net Income (TTM) was -23.29. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chembio Diagnostics's current Cash Flow from Operations (TTM) was -12.69. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec21)
=-23.29/73.252
=-0.31794354

ROA (Last Year)=Net Income/Total Assets (Dec20)
=-33.903/64.892
=-0.52245269

Chembio Diagnostics's return on assets of this year was -0.31794354. Chembio Diagnostics's return on assets of last year was -0.52245269. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chembio Diagnostics's current Net Income (TTM) was -23.29. Chembio Diagnostics's current Cash Flow from Operations (TTM) was -12.69. ==> -12.69 > -23.29 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=5.513/63.3978
=0.08695885

Gearing (Last Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=23.705/65.8354
=0.36006465

Chembio Diagnostics's gearing of this year was 0.08695885. Chembio Diagnostics's gearing of last year was 0.36006465. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec22)=Total Current Assets/Total Current Liabilities
=48.452/39.3
=1.23287532

Current Ratio (Last Year: Dec21)=Total Current Assets/Total Current Liabilities
=54.845/15.282
=3.58886271

Chembio Diagnostics's current ratio of this year was 1.23287532. Chembio Diagnostics's current ratio of last year was 3.58886271. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chembio Diagnostics's number of shares in issue this year was 36.488. Chembio Diagnostics's number of shares in issue last year was 30.112. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9.762/48.34
=0.20194456

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.431/36.926
=0.06583437

Chembio Diagnostics's gross margin of this year was 0.20194456. Chembio Diagnostics's gross margin of last year was 0.06583437. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec21)
=48.34/73.252
=0.65991372

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec20)
=36.926/64.892
=0.56903779

Chembio Diagnostics's asset turnover of this year was 0.65991372. Chembio Diagnostics's asset turnover of last year was 0.56903779. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chembio Diagnostics has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Chembio Diagnostics  (NAS:CEMI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chembio Diagnostics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chembio Diagnostics (Chembio Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Executives
Perceptive Credit Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko director 29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly officer: See Remarks 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff director 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari officer: Senior Vice President 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas officer: See Remarks 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D director STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman officer: Executive VP and CFO 3661 HORSEBLOCK RD, MEDFORD NY 11763

Chembio Diagnostics (Chembio Diagnostics) Headlines